Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$12.63
▼ $0.10 (-0.8%)
Market data updated: 09/20 06:38 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$3.87B
Day Range
$12.37 - $12.96
52-Week Range
$2.75 - $13.18
Beta
—
Next Earnings
04.11.2026
Support
$4.98
Resistance
$13.18
ABCL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+167.6% (1Y)
Strengths: 14/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 160.6%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$12.04 vs. price $12.63 (-195.3%)
Fair Value
Signal tension
Growth scores strong (70/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $12.63
Evidence: Euphoria score crossed 55 (now 58)
What happened after
Still awaiting outcome
today · $12.63
Evidence: FOMO score jumped from 22 to 51 day-over-day
What happened after
Still awaiting outcome
1d ago · $12.63
Evidence: Euphoria score crossed 55 (now 58)
What happened after
Still awaiting outcome
1d ago · $12.63
Evidence: FOMO score jumped from 22 to 51 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
70
Quality
42
Value
38
Momentum
79
Risk
48
Sentiment
80
Fundamental
30
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **AbCellera Biologics Inc.** has centered on its financial and strategic momentum, including a **$200 million stock offering** in early August 2026, which was oversubscribed. The company’s stock surged **64%** in August, driven by optimism over its **T-cell epitope (TCE) platform** and a potential partnership with **Vertex Pharmaceuticals**. Additionally, AbCellera’s collaboration with **Jazz Pharmaceuticals**—following an FDA approval—boosted investor confidence, though broader biotech sector trends also influenced market reactions. Upcoming presentations at the **Cantor Global Healthcare Conference** in September 2026 may further highlight its pipeline progress.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about AbCellera Biologics Inc. - Common. News trend score: 80. Reason: 6 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
52
🎯 Conviction (vs. Emotion)
53
Psychology
58
Fundamentals
30
Technical
79
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
+128%
Market Narrative
70
Fundamental Reality
53
Narrative Gap
+17
🧠 StockIQ Psychologist
The market behavior suggests ABCL is experiencing **herding** as its dominant state, driven by relative underperformance (-3.4%) compared to peers (-2.2%). While euphoria persists due to extreme valuation (+93.3% above 200-day average), the lack of momentum (-4.8% ROC) and neutral RSI (62) dampens blind optimism. The narrative gap (0) implies no misalignment between sentiment and fundamentals, but the disconnect between price performance and EPS growth (+0.1%) may signal caution. The key question: *Will herding sustain despite weak momentum, or will euphoria fade as valuation pressures mount?*
Updated: 09/09/2026, 02:28 PM
What could change this?
👥 What the crowd believes
"AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership."
"AbCellera shares rise after positive ABCL635 Phase 2 results"
"AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants"
🧠 Market Brain events driving this
📈 18D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 6/100
🗣️ Why do they disagree?
The stark contrast between Walter Bagehot’s near-perfect score and the overwhelmingly negative verdicts from the rest of the methodologies highlights a fundamental divide in how these investors assess risk and opportunity. Bagehot’s focus on liquidity and resilience in a credit crunch suggests he would see ABCL as a stable, defensive holding—one that could weather financial stress. In contrast, methodologies like Howard Marks’ (both cycle and general) and Gerald Loeb’s, which prioritize risk management and valuation discipline, uniformly flag the stock as overvalued or late-cycle, warning of potential downside. Meanwhile, Fisher, Lynch, and even Graham’s defensive criteria all signal a lack of the quality or margin of safety they demand, while Veblen and Mackay’s warnings about speculative bubbles or crowd-driven behavior further underscore a perception of speculative excess. The middle-ground scores from Smith, Nelson, and the efficient-market camp reflect uncertainty rather than conviction, suggesting ABCL lacks the clear edge or defensive traits needed to justify a strong buy.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 60
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 52
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 39
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 31
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 28
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 27
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 24
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 6
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-289.0%
Net Margin
-194.9%
EBITDA Margin
-289.0%
ROE
-15.1%
ROA
-10.8%
ROIC
—
EPS
-$0.49
Cash
$128.51M
Total Debt
—
Current Ratio
11.32
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$12.63
Estimated Fair Value (DCF)
-$12.04
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-195.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
14.7%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 14.7% | $-199.73M | $-183.23M |
| 2 | 11.7% | $-223.05M | $-187.74M |
| 3 | 8.6% | $-242.28M | $-187.09M |
| 4 | 5.6% | $-255.75M | $-181.18M |
| 5 | 2.5% | $-262.15M | $-170.38M |
Base FCF (last actual year)
$-174.07M
Terminal Value
$-4.13B
Present Value of Terminal Value
$-2.69B
Enterprise Value
$-3.60B
Net Debt
$0
Equity Value
$-3.60B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.24
Tangible Book Value per Share (Tangible NAV)
$2.95
Sentiment based on basic keywords (not AI) — 6 positive, 13 neutral, 1 negative out of the last 20 articles.
Yahoo · 16.9.2026
SeekingAlpha · 16.9.2026
Benzinga · 16.9.2026
Yahoo · 2.9.2026
Business Wire · 2.9.2026
Benzinga · 25.8.2026
Benzinga · 25.8.2026
SeekingAlpha · 16.8.2026
Insider Monkey · 16.8.2026
Insider Monkey · 14.8.2026
MT Newswires · 13.8.2026
MT Newswires · 13.8.2026
Business Wire · 13.8.2026
Motley Fool · 13.8.2026
Benzinga · 12.8.2026
Benzinga · 12.8.2026
Simply Wall St. · 12.8.2026
Simply Wall St. · 12.8.2026
MT Newswires · 11.8.2026
Simply Wall St. · 11.8.2026
AbCellera Biologics Inc. - Common (ABCL) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ABCL currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ABCL's estimated fair value is -$12.04, which is 195.3% below the current price of $12.63. This is one valuation model among several signals in the fair-value category, not a price target.
ABCL's technical score is 79/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 160.6%; Current ratio: 11.32; Price is above the 50-day average.
Based on the real signals StockIQ computed: Estimated fair value: -$12.04 vs. price $12.63 (-195.3%); Operating margin: -289.0% (negative); Net margin: -194.9% (negative).
StockIQ has no recorded dividend payment history for ABCL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 9 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hayden Michael R | Open Market Purchase | 24.8.2026 | 1,373,397 | +53,613 | $10.64 |
| Hayden Michael R | Open Market Purchase | 24.8.2026 | 53,613 | +53,613 | $10.64 |
| Montalbano John S. | Open Market Purchase | 18.8.2026 | 10,000 | +10,000 | $11.03 |
| Booth Andrew | Open Market Purchase | 14.8.2026 | 37,200 | +37,200 | $10.32 |
| Booth Andrew | Open Market Purchase | 14.8.2026 | 482,800 | +37,200 | $10.32 |
| Hayden Michael R | Open Market Purchase | 12.8.2026 | 46,387 | +46,387 | $10.37 |
| Hayden Michael R | Open Market Purchase | 12.8.2026 | 1,319,784 | +46,387 | $10.37 |
| Hayden Michael R | Gift | 11.8.2026 | 50,000 | -50,000 | — |
| Hayden Michael R | Gift | 11.8.2026 | 1,273,397 | -50,000 | — |
| Sandor Victor | Grant/Award from Employer | 1.7.2026 | 152,207 | +152,207 | — |
| Seely Lynn | Grant/Award from Employer | 1.7.2026 | 152,207 | +152,207 | — |
| Seely Lynn | Grant/Award from Employer | 1.7.2026 | 152,207 | +152,207 | — |
| Sandor Victor | Grant/Award from Employer | 1.7.2026 | 152,207 | +152,207 | — |
| Montalbano John S. | Grant/Award from Employer | 11.6.2026 | 111,701 | +111,701 | — |
| Quake Stephen | Grant/Award from Employer | 11.6.2026 | 111,701 | +111,701 | — |
| Hayden Michael R | Grant/Award from Employer | 11.6.2026 | 111,701 | +111,701 | — |
| Hayden Michael R | Grant/Award from Employer | 11.6.2026 | 1,011,544 | +111,701 | — |
| Quake Stephen | Grant/Award from Employer | 11.6.2026 | 306,633 | +111,701 | — |
| Montalbano John S. | Grant/Award from Employer | 11.6.2026 | 1,141,544 | +111,701 | — |
| Booth Andrew | Exercise of Derivative Securities | 3.6.2026 | 250,000 | -250,000 | — |
| Booth Andrew | Exercise of Derivative Securities | 3.6.2026 | 250,000 | +250,000 | $0.19 |
| Booth Andrew | Exercise of Derivative Securities | 3.6.2026 | 445,600 | +250,000 | $0.19 |
| Booth Andrew | Exercise of Derivative Securities | 3.6.2026 | 8,501,849 | -250,000 | — |
| Montalbano John S. | Open Market Purchase | 14.5.2026 | 20,000 | +20,000 | $4.77 |
| Montalbano John S. | Open Market Purchase | 14.5.2026 | 241,000 | +20,000 | $4.77 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
34,752,708 shares short as of 2026-08-31 · vs. 48,318,516 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.4% of trading volume this week was short selling, vs. 43.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology